MicroRNA-133b Targets Glutathione S-transferase π Expression to Increase Ovarian Cancer Cell Sensitivity to Chemotherapy Drugs

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2015 Sep 24

PMID 26396496

Citations 49

Authors

Shuo Chen

Jin-Wen Jiao

Kai-Xuan Sun

Zhi-Hong Zong

Yang Zhao

Affiliations

Soon will be listed here.

Abstract

Background: Accumulating studies reveal that aberrant microRNA (miRNA) expression can affect the development of chemotherapy drug resistance by modulating the expression of relevant target proteins. The aim of this study was to investigate the role of miR-133b in the development of drug resistance in ovarian cancer cells.

Methods: We examined the levels of miR-133b expression in ovarian carcinoma tissues and the human ovarian carcinoma cell lines (A2780, A2780/DDP and A2780/Taxol, respectively). We determined the cell viability of these cell lines treated with cisplatin or paclitaxel in the presence or absence of miR-133b or anti-miR-133b transfection using the MTT assay. Reverse transcription polymerase chain reaction and Western blotting were used to assess the mRNA and protein expression levels of two drug-resistance-related genes: glutathione S-transferase (GST)-π and multidrug resistance protein 1 (MDR1). The dual-luciferase reporter assay was used to detect the promoter activity of GST-π in the presence and absence of miR-133b.

Results: The expression of miR-133b was significantly lower in primary resistant ovarian carcinomas than in the chemotherapy-sensitive carcinomas (P<0.05), and the same results were found in primary resistant ovarian cell lines (A2780/Taxol and A2780/DDP) compared to the chemotherapy-sensitive cell line (A2780; P<0.05). Following miR-133b transfection, four cell lines showed increased sensitivity to paclitaxel and cisplatin, while anti-miR-133b transfection reduced cell sensitivity to paclitaxel and cisplatin. Dual-luciferase reporter assay showed that miR-133b interacted with the 3'-untranslated region of GST-π. Compared to controls, the mRNA and protein levels of MDR1 and GST-π were downregulated after miR-133b transfection and upregulated after anti-miR-133b transfection.

Conclusion: MicroRNA-133b may reduce ovarian cancer drug resistance by silencing the expression of the drug-resistance-related proteins, GST-π and MDR1. In future, the combination of miR-133b with chemotherapy agents may prevent the development of drug resistance in ovarian cancers.

Citing Articles

MiRNAs: main players of cancer drug resistance target ABC transporters.

Mohammadi F, Nejatollahi M, Sheikhnia F, Ebrahimi Y, Mohammadi M, Rashidi V Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39808313 DOI: 10.1007/s00210-024-03719-y.

Molecular mechanisms of cisplatin resistance in ovarian cancer.

Jiang C, Shen C, Ni M, Huang L, Hu H, Dai Q Genes Dis. 2024; 11(6):101063.

PMID: 39224110 PMC: 11367050. DOI: 10.1016/j.gendis.2023.06.032.

Therapeutic Chemoresistance in Ovarian Cancer: Emerging Hallmarks, Signaling Mechanisms and Alternative Pathways.

Zaib S, Javed H, Rana N, Zaib Z, Iqbal S, Khan I Curr Med Chem. 2024; 32(5):923-938.

PMID: 38275065 DOI: 10.2174/0109298673276871231205043417.

Research progress of circulating non-coding RNA in diagnosis and treatment of hepatocellular carcinoma.

You J, Xia H, Huang Z, He R, Zhao X, Chen J Front Oncol. 2023; 13:1204715.

PMID: 37546394 PMC: 10400719. DOI: 10.3389/fonc.2023.1204715.

Natural Compounds and Glutathione: Beyond Mere Antioxidants.

Di Giacomo C, Malfa G, Tomasello B, Bianchi S, Acquaviva R Antioxidants (Basel). 2023; 12(7).

PMID: 37507985 PMC: 10376414. DOI: 10.3390/antiox12071445.

References

Sharma A, Raina V, Lokeshwar N, Deo S, Shukla N, Mohanti B . Phase II study of cisplatin, etoposide and paclitaxel in locally advanced or metastatic adenocarcinoma of gastric/gastroesophageal junction. Indian J Cancer. 2006; 43(1):16-9. DOI: 10.4103/0019-509x.25770. View

Allegra A, Alonci A, Campo S, Penna G, Petrungaro A, Gerace D . Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol. 2012; 41(6):1897-912. DOI: 10.3892/ijo.2012.1647. View

Guo H, Ingolia N, Weissman J, Bartel D . Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010; 466(7308):835-40. PMC: 2990499. DOI: 10.1038/nature09267. View

Qin W, Dong P, Ma C, Mitchelson K, Deng T, Zhang L . MicroRNA-133b is a key promoter of cervical carcinoma development through the activation of the ERK and AKT1 pathways. Oncogene. 2011; 31(36):4067-75. DOI: 10.1038/onc.2011.561. View

Popeda M, Pluciennik E, Bednarek A . [Proteins in cancer multidrug resistance]. Postepy Hig Med Dosw (Online). 2014; 68:616-32. DOI: 10.5604/17322693.1103268. View

He J, Yu J, Xu Q, Wang L, Zheng J, Liu L . Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy. Autophagy. 2015; 11(2):373-84. PMC: 4502709. DOI: 10.1080/15548627.2015.1009781. View

Andorfer P, Rotheneder H . Regulation of the MDR1 promoter by E2F1 and EAPP. FEBS Lett. 2013; 587(10):1504-9. DOI: 10.1016/j.febslet.2013.03.026. View

Januchowski R, Wojtowicz K, Sujka-Kordowska P, Andrzejewska M, Zabel M . MDR gene expression analysis of six drug-resistant ovarian cancer cell lines. Biomed Res Int. 2013; 2013:241763. PMC: 3591129. DOI: 10.1155/2013/241763. View

Chen X, Wang K, Xu Z, Li S, Liu Q, Fu D . MiR-133b regulates bladder cancer cell proliferation and apoptosis by targeting Bcl-w and Akt1. Cancer Cell Int. 2014; 14:70. PMC: 4238049. DOI: 10.1186/s12935-014-0070-3. View

10.

Zhang T, Guan M, Jin H, Lu Y . Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells. Gynecol Oncol. 2005; 97(2):501-7. DOI: 10.1016/j.ygyno.2005.01.027. View

11.

Guo L, Bai H, Zou D, Hong T, Liu J, Huang J . The role of microRNA-133b and its target gene FSCN1 in gastric cancer. J Exp Clin Cancer Res. 2014; 33:99. PMC: 4272783. DOI: 10.1186/s13046-014-0099-0. View

12.

Ma M, He M, Wang Y, Jiao X, Zhao L, Bai X . MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). Cancer Lett. 2013; 339(1):107-15. DOI: 10.1016/j.canlet.2013.07.016. View

13.

Wang Q, Wang Z, Chu L, Li X, Kan P, Xin X . The Effects and Molecular Mechanisms of MiR-106a in Multidrug Resistance Reversal in Human Glioma U87/DDP and U251/G Cell Lines. PLoS One. 2015; 10(5):e0125473. PMC: 4423781. DOI: 10.1371/journal.pone.0125473. View

14.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

15.

Beeghly A, Katsaros D, Chen H, Fracchioli S, Zhang Y, Massobrio M . Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol Oncol. 2005; 100(2):330-7. DOI: 10.1016/j.ygyno.2005.08.035. View

16.

Sotillo E, Thomas-Tikhonenko A . Shielding the messenger (RNA): microRNA-based anticancer therapies. Pharmacol Ther. 2011; 131(1):18-32. PMC: 3124007. DOI: 10.1016/j.pharmthera.2011.04.006. View

17.

Xu H, Shen H, Li H . microRNA-106a modulates cisplatin sensitivity by targeting PDCD4 in human ovarian cancer cells. Oncol Lett. 2013; 7(1):183-188. PMC: 3861584. DOI: 10.3892/ol.2013.1644. View

18.

Esquela-Kerscher A, Slack F . Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6(4):259-69. DOI: 10.1038/nrc1840. View

19.

van Jaarsveld M, Helleman J, Boersma A, van Kuijk P, van Ijcken W, Despierre E . miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene. 2012; 32(36):4284-93. DOI: 10.1038/onc.2012.433. View

20.

Xing A, Shi D, Liu W, Chen X, Sun Y, Wang X . Restoration of chemosensitivity in cancer cells with MDR phenotype by deoxyribozyme, compared with ribozyme. Exp Mol Pathol. 2013; 94(3):481-5. DOI: 10.1016/j.yexmp.2013.03.004. View